Page 12 - ஆரோக்கியம் விளைவுகள் ஆஃப் புகைத்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2020 financial results and provided an update on the cytisinicline clinical development program. Recent Events & Highlights Initiated the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites in the United States Presented data on smoker and e-cigarette user attitudes and perceptions on quitting at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting on February 24, 2021

United statesBritish columbiaJason wongJohn bencichUs department of healthHuman servicesWorld health organizationExchange commissionSociety for research on nicotineHealth consequences of smokingLife sciences incAchieve life sciencesAnnual meetingChief executive officerHighlighting smoker dissatisfactionAvailable treatments presented